Disease Biomarkers in Multiple Sclerosis

@article{Harris2012DiseaseBI,
  title={Disease Biomarkers in Multiple Sclerosis},
  author={V. K. Harris and S. A. Sadiq},
  journal={Molecular Diagnosis & Therapy},
  year={2012},
  volume={13},
  pages={225-244}
}
  • V. K. Harris, S. A. Sadiq
  • Published 2012
  • Medicine
  • Molecular Diagnosis & Therapy
  • Multiple sclerosis (MS) is an autoimmune disorder of the brain and spinal cord that predominantly affects white matter. MS has a variable clinical presentation and has no ‘diagnostic’ laboratory test; this often results in delays to definite diagnosis. In confronting the disease, early diagnosis and appropriate, timely therapeutic intervention are critical factors in ensuring favorable long-term outcomes.The availability of reliable biomarkers could radically alter our management of MS at… CONTINUE READING
    27 Citations
    Clinical biomarkers in multiple sclerosis.
    • 4
    Gene expression signatures: biomarkers toward diagnosing multiple sclerosis
    • 26
    • PDF
    Biomarkers of Disorders of the Nervous System
    • 1
    Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations.
    • 3
    • PDF

    References

    SHOWING 1-10 OF 219 REFERENCES
    Identification of molecular biomarkers for multiple sclerosis.
    • 27
    • PDF
    Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.
    • 584
    • PDF
    Lack of association between antimyelin antibodies and progression to multiple sclerosis.
    • 146
    Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis
    • 37
    Cerebrospinal fluid proteome profile in multiple sclerosis
    • 65
    Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis
    • 214
    • PDF
    Epidemiology and natural history of multiple sclerosis: new insights
    • 170
    • PDF
    Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis
    • 54
    Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS
    • 58